Strides Pharma Science Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹452.75
- Today's High:
- ₹476.25
- Open Price:
- ₹472.45
- 52W Low:
- ₹267.4926
- 52W High:
- ₹487.1972
- Prev. Close:
- ₹471.95
- Volume:
- 45785
Company Statistics
- Market Cap.:
- ₹39.67 billion
- Book Value:
- 245.755
- Revenue TTM:
- ₹36.78 billion
- Operating Margin TTM:
- 8%
- Gross Profit TTM:
- ₹19.30 billion
- Profit Margin:
- -2.01%
- Return on Assets TTM:
- 1.72%
- Return on Equity TTM:
- -10.14%
Company Profile
Strides Pharma Science Limited had its IPO on under the ticker symbol STAR.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Strides Pharma Science Limited has a staff strength of 2,850 employees.
Stock update
Shares of Strides Pharma Science Limited opened at ₹472.45 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹452.75 - ₹476.25, and closed at ₹456.75.
This is a -3.22% slip from the previous day's closing price.
A total volume of 45,785 shares were traded at the close of the day’s session.
In the last one week, shares of Strides Pharma Science Limited have increased by +3.02%.
Strides Pharma Science Limited's Key Ratios
Strides Pharma Science Limited has a market cap of ₹39.67 billion, indicating a price to book ratio of 1.4095 and a price to sales ratio of 0.9481.
In the last 12-months Strides Pharma Science Limited’s revenue was ₹36.78 billion with a gross profit of ₹19.30 billion and an EBITDA of ₹5.51 billion. The EBITDA ratio measures Strides Pharma Science Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Strides Pharma Science Limited’s operating margin was 8% while its return on assets stood at 1.72% with a return of equity of -10.14%.
In Q2, Strides Pharma Science Limited’s quarterly earnings growth was a positive 2719.5% while revenue growth was a negative 1.1%.
Strides Pharma Science Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-10.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Strides Pharma Science Limited’s profitability.
Strides Pharma Science Limited stock is trading at a EV to sales ratio of 1.6497 and a EV to EBITDA ratio of -664.4477. Its price to sales ratio in the trailing 12-months stood at 0.9481.
Strides Pharma Science Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0.34% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹66.38 billion
- Total Liabilities
- ₹29.90 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Strides Pharma Science Limited ended 2024 with ₹66.38 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹66.38 billion while shareholder equity stood at ₹22.12 billion.
Strides Pharma Science Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹29.90 billion in other current liabilities, in common stock, ₹-2003270000.00 in retained earnings and ₹5.14 billion in goodwill. Its cash balance stood at ₹3.04 billion and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹11.40 billion.
Strides Pharma Science Limited’s total current assets stands at ₹32.43 billion while long-term investments were ₹0 and short-term investments were ₹1.55 billion. Its net receivables were ₹12.99 billion compared to accounts payable of ₹9.82 billion and inventory worth ₹11.47 billion.
In 2024, Strides Pharma Science Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Strides Pharma Science Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹456.75
- 52-Week High
- ₹487.1972
- 52-Week Low
- ₹267.4926
- Analyst Target Price
- ₹
Strides Pharma Science Limited stock is currently trading at ₹456.75 per share. It touched a 52-week high of ₹487.1972 and a 52-week low of ₹487.1972. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹443.36 and 200-day moving average was ₹363.94 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 2740.5% of the company’s stock are held by insiders while 2570.9% are held by institutions.
Frequently Asked Questions About Strides Pharma Science Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company has a strategic partnership with Orbicular Pharmaceutical Technologies Private Limited to develop, manufacture, and commercialize nasal sprays. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.